Arctoris strengthens senior team to continue the development of its on-demand drug discovery services. Joining Arctoris in senior roles are Professor John Mattick, Member of the Board of Directors (left) & Dr Daniel Thomas, Head of Discovery Biology (right)
OXFORD, UK – 13 November 2019 Arctoris Ltd today announced the appointment of Professor John Mattick AO FAA FTSE FAHMS FRSN HonFRCPA GAICD as a Member of the Board of Directors, and Daniel Thomas PhD LCGI as Head of Discovery Biology. Arctoris is strengthening its senior team while the company is growing its commercial operations and service portfolio to enable more customers to rapidly reach their next drug discovery milestone.
Martin-Immanuel Bittner MD DPhil, Chief Executive Officer and Co-Founder of Arctoris, commented: “I am delighted to welcome Professor Mattick and Dr Thomas to our senior team. Their depth of expertise and experience will enable us to further develop Arctoris’s revolutionary drug discovery platform for customers and partners around the world. I look forward to working closely with them to enhance our novel capabilities and services.”
As the former Chief Executive Officer of Genomics England and the former Executive Director of the Garvan Institute of Medical Research in Sydney, Professor Mattick is a leading expert on how the power of technological advances can transform the discovery and delivery of new therapeutic approaches. He has published over 300 research articles and reviews, which have been cited over 64,000 times, and has received numerous awards for his contributions to the field of molecular biology. With this significant scientific and strategic insight, his appointment to the board of Arctoris will support the development of the company’s pre-optimised and fully validated research and development processes.
“I am delighted to join the Board of Directors of Arctoris. Its fully automated platform allows access to a wide range of methods and technologies, new levels of reproducibility, and exceptional data capture and integration capabilities that are unavailable elsewhere, which will transform biomedical research and drug discovery.” said Professor John Mattick, Member of the Board of Directors, Arctoris.
Daniel Thomas, Head of Discovery Biology, Arctoris, added: “Generating high-quality, reproducible data while balancing cost, scale and complexity is a fundamental challenge faced by the global drug discovery community today. Having experienced these pressures first-hand, I am committed to helping our customers and partners by configuring, running and monitoring experiments in real-time through Arctoris’s fully automated drug discovery platform.”
Daniel Thomas joins Arctoris with more than 20 years’ experience working in early stage small molecule drug discovery with GlaxoSmithKline. He brings with him an extensive theoretical and practical knowledge of assay development and mechanistic profiling together with an accomplished leadership track record developing trans-national matrix research teams. He also has significant experience in the implementation of transformative technologies and the delivery of key mechanistic data across a broad range of therapeutic areas.
About Arctoris Ltd
Arctoris Ltd is an Oxford-based research company that is revolutionising drug discovery for virtual and traditional biotechnology companies, pharmaceutical corporations and academia. Arctoris has established the world’s first fully automated drug discovery platform, offering pre-optimised and fully validated processes for its partners and customers globally. Accessible remotely, the platform provides on-demand access to a wide range of biochemical, cell biology and molecular biology assays conducted by robotics, enabling rapid, informed decision-making in basic biology, target validation, toxicology and phenotypic screening. These assay capabilities are accessed using a powerful online portal that streamlines experiment planning, ordering, tracking and data analysis. Thanks to the Arctoris platform, customers can rapidly, accurately and cost-effectively perform their research and advance their drug discovery programmes.
For media enquiries, please contact:
Head of Office
READY TO GET STARTED?
To find out how to accelerate your project timelines and generate higher quality data, reach out to us today.